EMA recommends Glaxo's melanoma med Mekinist; Merck forms digital partnership to track vaccine use;

> The European Medicines Agency (EMA) has recommended approval of GlaxoSmithKline's ($GSK) Mekinist as a treatment for melanoma. Release

> Roche ($RHHBY) has nabbed EU approval for a new subcutaneous formulation of rheumatoid arthritis treatment RoActemra. Release

> Augé Reichenberg has joined McCann HumanCare as its executive creative director. Release

> Merck ($MRK) has partnered with electronic health record provider Practice Fusion to help doctors track whether patients are up-to-date on their vaccines. More

> The FDA is reviewing the risks and side effects associated with Pfizer's ($PFE) anti-smoking drug Chantix. More

> Remarketing and consulting specialist Generic Pharma 2.0 have formed a strategic alliance. Report

> Philadelphia's Star Group has merged with healthcare marketing agencies Vox Medica and Calcium NYC. More

And Finally... How should Sun Pharma, the new owner of troubled Ranbaxy, handle its tarnished name? More (sub. req.)

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.